Cite

HARVARD Citation

    Cremer, P. et al. (2021). Double-blind randomized proof-of-concept trial of canakinumab in patients with COVID-19 associated cardiac injury and heightened inflammation. European Heart Journal Open. 1 (1), p. . [Online]. 
  
Back to record